The Niche Episode 004 – Abbott, Roche, and Encoded Therapeutics

Abbott and the FDA develop digital healthcare, Roche gives us some market insight, and we look at Encoded’s approach to gene therapy. 

Sponsors
www.thescopemethod.com

Story References
https://www.roche.com/dam/jcr:5c6df314-831e-4601-9f72-617d28d05e1e/en/23072020_MR_Q2_EN.pdf
https://abbott.mediaroom.com/2020-07-23-Abbott-Receives-FDA-Approval-for-iOS-Compatible-App-Allowing-People-Living-With-Chronic-Pain-and-Movement-Disorders-to-Personalize-Therapy-Via-Their-Mobile-Device
https://encoded.com/encoded-therapeutics-announces-135-million-series-d-financing-to-support-first-clinical-trials-in-scn1a-dravet-syndrome-and-advance-preclinical-pipeline-of-gene-therapies-for-debilitating-neurologic/
 

Music by Luke Goodson
www.soundcloud.com/lukegoodson

The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.

The Niche Episode 003 – BeiGene, ALS, Moderna, and Rheumatoid Arthritis

Today on The Niche, big deals in Chinese big-pharma as BeiGene raises another $2 billion, Biogen and Moderna both release papers on crucial clinical trials, and a new cell-type could play a pivotal role in rheumatoid arthritis.

Sponsors
www.thescopemethod.com

Story References
http://ir.beigene.com/static-files/ec5456b7-8cc2-4b88-8a65-e7d727a0b574
https://www.mayoclinic.org/diseases-conditions/amyotrophic-lateral-sclerosis/symptoms-causes/syc-20354022
https://investors.biogen.com/news-releases/news-release-details/biogen-present-new-interim-data-its-phase-12-clinical-study
https://www.nejm.org/doi/full/10.1056/NEJMoa2003715
https://www.nejm.org/doi/full/10.1056/NEJMoa2004114?rss=searchAndBrowse
https://www.nejm.org/doi/full/10.1056/NEJMoa2022483

Music by Luke Goodson
www.soundcloud.com/lukegoodson

The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.

The Niche Episode 002 – Aducanumab, PPD, and Gilead

Today on The Niche Pod, Biogen has submitted their Alzheimer’s drug aducanumab to the FDA, we take a look at the fate of PPD since their February IPO, and explore Gilead’s not-a-claim claims on their COVID-19 treatment.

Sponsors
www.thescopemethod.com

Story References
https://doi.org/10.1016/j.cct.2018.01.003
https://www.ppd.com/
https://www.businesswire.com/news/home/20200514005477/en/PPD-Honored-Quality-Capabilities-CRO-Leadership-Awards
https://www.clinicaltrialsarena.com/comment/biogen-aducanumab-fda-approval-alzheimers/
https://www.fiercebiotech.com/biotech/a-test-for-hahn-s-fda-biogen-submits-controversial-alzheimer-s-drug-aducanumab
https://www.gilead.com/news-and-press/press-room/press-releases/2020/7/gilead-presents-additional-data-on-investigational-antiviral-remdesivir-for-the-treatment-of-covid-19

Music by Luke Goodson
www.soundcloud.com/lukegoodson

The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.

The Niche Episode 001 – Gene Therapy Deaths, FDA Guidelines, and CRISPR Tech

Today on The Niche we will be discussing two deaths in a gene therapy trial, new COVID-19 vaccine guidelines from the FDA, and recent developments in CRISPR-Cas gene editing technologies.

Story References
https://www.liebertpub.com/doi/10.1089/hum.2020.182
https://www.fda.gov/media/139638/download
https://apnews.com/dacdc8bc428dd4df6511bfa259cfec44
https://doi.org/10.1126/science.abb6151

Music by Luke Goodson
https://soundcloud.com/lukegoodson

The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.

The Niche Episode 000 – What is The Niche Podcast?

Interested in The Niche Podcast? Start here to learn what to expect! 

The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.